Top

Published in:

01-11-2011 | Epidemiology

Association between polymorphisms of the renin–angiotensin system genes and breast cancer risk: a meta-analysis

Authors: Bo Xi, Tao Zeng, Liu Liu, Yajun Liang, Weina Liu, Yuehua Hu, Jun Li

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

The renin–angiotensin system (RAS) has been considered to be implicated in the development of breast cancer. However, the results are inconsistent. In this study, we conducted a meta-analysis to assess the association between four polymorphisms, including angiotensin I-converting enzyme (ACE) I/D and A240T, angiotensin II type 1 receptor (AGTR1) A1166C and angiotensinogen (AGT) M235T polymorphisms, and breast cancer risk. Published literature from PubMed, ISI web of science, and Embase databases were retrieved. All studies evaluating the association between ACE I/D, ACE A240T, AGTR1 A1166C, or AGT M235T polymorphism and breast cancer risk were included. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model. Ten studies (1,650 cases and 9,283 controls) on ACE I/D polymorphism, six studies (1,316 cases and 2,632 controls) on ACE A240T polymorphism, three studies (235 cases and 601 controls) on AGTR1 A1166C polymorphism, and two studies (273 cases and 3,547 controls) on AGT M235T polymorphism were included. Overall, the meta-analysis showed no significant association between I/D or A240T polymorphism and breast cancer risk in either genetic model. Further subgroup analysis by ethnicity also revealed non-significant association in Caucasian or Asian populations except for Africans (the statistically significant association for ACE I/D or A240T polymorphism in Africans derived from only one study). A marginally significant association was observed for AGTR1 A1166C polymorphism in Caucasians (CC vs. AA: OR = 0.31, 95% CI 0.10–0.99). In addition, there was a significant association between AGT M235T polymorphism and breast cancer risk in Caucasians (OR = 1.45, 95% CI 1.12–1.88). The present meta-analysis suggested that ACE I/D and A240T polymorphisms might not be a good predictor of breast cancer risk, while AGTR1 A1166C and AGT M235T polymorphisms might be implicated in the pathogenesis of breast cancer. Given the limited sample size, the findings warrant further investigation.

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef

Travis RC, Reeves GK, Green J, Bull D, Tipper SJ, Baker K, Beral V, Peto R, Bell J, Zelenika D, Lathrop M, Million Women Study Collaborators (2010) Gene–environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375(9732):2143–2151PubMedCrossRef

Narod SA (2010) Genes, the environment, and breast cancer. Lancet 375(9732):2123–2124PubMedCrossRef

Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4(3):174–191PubMedCrossRef

Eccles D, Tapper W (2010) The influence of common polymorphisms on breast cancer. Cancer Treat Res 155:15–32PubMedCrossRef

Timmermans PB, Chiu AT, Herblin WF, Wong PC, Smith RD (1992) Angiotensin II receptor subtypes. Am J Hypertens 5(6 Pt 1):406–410PubMed

Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16(7):293–299PubMedCrossRef

Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F (1996) Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 58(6):1268–1278PubMed

Sadoshima J, Aoki H, Izumo S (1997) Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res 80(2):228–241PubMed

10.

Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352(9123):179–184PubMedCrossRef

11.

Célérier J, Cruz A, Lamandé N, Gasc JM, Corvol P (2002) Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 39(2):224–228PubMedCrossRef

12.

Gould AB, Green D (1971) Kinetics of the human renin and human substrate reaction. Cardiovasc Res 5(1):86–89PubMedCrossRef

13.

Niu W, Qi Y (2010) Association of the angiotensin II type I receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. Hypertens Res 33(11):1137–1143PubMedCrossRef

14.

Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC (2005) Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26(2):459–464PubMedCrossRef

15.

Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC (2003) Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 63(3):573–578PubMed

16.

Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE (2003) Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res 63(20):6984–6987PubMed

17.

Yuan JM, Koh WP, Sun CL, Lee HP, Yu MC (2005) Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26(8):1389–1394PubMedCrossRef

18.

González-Zuloeta Ladd AM, Arias Vásquez A, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, Stricker B, van Duijn C (2005) Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14(9):2143–2146PubMedCrossRef

19.

Yaren A, Turgut S, Kursunluoglu R, Oztop I, Turgut G, Kelten C, Erdem E (2006) Association between the polymorphism of the angiotensin-converting enzyme gene and tumor size of breast cancer in premenopausal patients. Tohoku J Exp Med 210(2):109–116PubMedCrossRef

20.

Yaren A, Turgut S, Kursunluoglu R, Oztop I, Turgut G, Degirmencioglu S, Kelten C, Erdem E (2007) Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J Investig Med 55(5):255–261PubMedCrossRef

21.

van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH (2008) Renin–angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 112(4):748–757PubMedCrossRef

22.

Alves Corrêa SA, Ribeiro de Noronha SM, Nogueira-de-Souza NC, Valleta de Carvalho C, Massad Costa AM, Juvenal Linhares J, Vieira Gomes MT, Guerreiro da Silva ID (2009) Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J Renin Angiotensin Aldosterone Syst 10(1):51–58PubMedCrossRef

23.

Mendizábal-Ruiz AP, Morales JA, Castro Marti Nez X, Gutierrez Rubio SA, Valdez L, Vásquez-Camacho JG, Sanchez Corona J, Moran Moguel MC (2010) RAS polymorphisms in cancerous and benign breast tissue. J Renin Angiotensin Aldosterone Syst. doi: 10.1177/1470320310383735

24.

Namazi S, Monabati A, Ardeshir-Rouhani-Fard S, Azarpira N (2010) Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in Iranian population. Mol Carcinog 49(12):1022–1030PubMedCrossRef

25.

González-Zuloeta Ladd AM, Arias Vásquez A, Siemes C, Yazdanpanah M, Coebergh JW, Hofman A, Stricker BH, van Duijn CM (2007) Differential roles of Angiotensinogen and Angiotensin Receptor type 1 polymorphisms in breast cancer risk. Breast Cancer Res Treat 101(3):299–304PubMedCrossRef

26.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef

27.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

28.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed

29.

Ager EI, Neo J, Christophi C (2008) The renin–angiotensin system and malignancy. Carcinogenesis 29(9):1675–1684PubMedCrossRef

30.

Ruiter R, Visser LE, Van Duijn CM, Ch Stricker BH (2011) The ACE insertion/deletion polymorphism and risk of cancer, a review and meta-analysis of the literature. Curr Cancer Drug Targets 11(4):421–430

31.

Röcken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, Krüger S, Malfertheiner P, Roessner A, Ebert MP (2005) The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 11(7):2526–2530PubMedCrossRef

32.

Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C, Roessner A, Stolte M, Malfertheiner P, Röcken C (2005) The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 14(12):2987–2989PubMedCrossRef

33.

Goto Y, Ando T, Nishio K, Ishida Y, Kawai S, Goto H, Hamajima N (2005) The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis. Asian Pac J Cancer Prev 6(4):464–467PubMed

34.

Sugimoto M, Furuta T, Shirai N, Ikuma M, Sugimura H, Hishida A (2006) Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol Biomarkers Prev 15(10):1929–1934PubMedCrossRef

35.

Röcken C, Neumann K, Carl-McGrath S, Lage H, Ebert MP, Dierkes J, Jacobi CA, Kalmuk S, Neuhaus P, Neumann U (2007) The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 9(9):716–722PubMedCrossRef

36.

Nikiteas N, Tsigris C, Chatzitheofylaktou A, Yannopoulos A (2007) No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme. In Vivo 21(6):1065–1068PubMed

37.

Toma M, Cimponeriu D, Apostol P, Stavarachi M, Cojocaru M, Belusică L, Crăciun AM, Radu I, Gavrilă L (2009) Lack of association between ACE ID polymorphism and colorectal cancer in Romanian patients. Chirurgia (Bucur) 104(5):553–556

38.

Cheon KT, Choi KH, Lee HB, Park SK, Rhee YK, Lee YC (2000) Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 178(6):351–360PubMedCrossRef

39.

Nacak M, Nacak I, Sanli M, Ozkur M, Pektaş M, Aynacioğlu AS (2010) Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Cancer Genet Cytogenet 198(1):22–26PubMedCrossRef

40.

Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, Lopes C (2004) Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol 202(3):330–335PubMedCrossRef

41.

Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T (2007) Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res 27(2):933–936PubMed

42.

Sierra Díaz E, Sánchez Corona J, Rosales Gómez RC, Gutierrez Rubio SA, Vázquez Camacho JG, Solano Moreno H, Morán Moguel MC (2009) Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J Renin Angiotensin Aldosterone Syst 10(4):241–246PubMedCrossRef

Title: Association between polymorphisms of the renin–angiotensin system genes and breast cancer risk: a meta-analysis
Authors: Bo Xi
Tao Zeng
Liu Liu
Yajun Liang
Weina Liu
Yuehua Hu
Jun Li
Publication date: 01-11-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1602-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

Anti-cytokeratin CAM 5.2 (B.D. Biosciences) has a primary reactivity with CK 7 and CK 8 (48 and 52 kD) rather than with the smaller molecular weight keratin breakdown fractions (50, 43, and 38 kD)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer